# Flerie

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/flerie).

## Overview

Flerie is a Stockholm-based life science investment company that owns and develops a portfolio of biotech, pharmaceutical, and related healthcare businesses. Its portfolio is organized around companies in product development and companies in commercial growth, with investments across Europe, Israel, and the United States.

## Products & services

• Active ownership and board-level support for portfolio companies
• Capital investment in private biotech and pharma companies
• Support for partnering, licensing, and commercialization
• Portfolio construction across development-stage and commercial life science assets

- **Product Development Investments** (78%) — Early and mid-stage biotech, pharma, and product companies advancing toward clinical proof-of-concept and approvals.
- **Commercial Growth Investments** (22%) — Companies already selling products or services and scaling market share in life science markets.

- Active ownership and board-level support for portfolio companies
- Capital investment in private biotech and pharma companies
- Support for partnering, licensing, and commercialization
- Portfolio construction across development-stage and commercial life science assets

## Customers

Flerie’s direct counterparties are the founders, management teams, and boards of its portfolio companies rather than end consumers. The underlying portfolio companies serve patients, healthcare providers, and life science customers through drug development, manufacturing, and specialized services. Flerie also serves its own shareholders by providing listed exposure to a diversified life science portfolio.

- **Portfolio company management teams** (primary) — They receive capital, governance support, and strategic input to advance development and commercialization.
- **Founders and co-investors** (primary) — They partner with Flerie in financing rounds and value-creation initiatives across the portfolio.
- **Patients and healthcare providers** (secondary) — They are the end beneficiaries of the drugs, diagnostics, and life science solutions developed by portfolio companies.
- **Life science service and technology customers** (secondary) — They buy enabling technologies, tools, or specialized services from commercial growth holdings.
- **Public shareholders** (primary) — They buy Flerie shares to gain diversified, listed exposure to private life science investing.

- Founders and management teams of biotech and pharma portfolio companies
- Boards and syndicate investors involved in portfolio financings
- Patients and healthcare systems served by portfolio company products
- Life science customers buying enabling technologies and services
- Public shareholders seeking listed exposure to private life science assets

## Geography

Flerie is based in Stockholm and manages a portfolio with exposure to several European markets, Israel, and the United States. Its business is therefore shaped by cross-border portfolio ownership, local regulatory regimes, and access to specialist life science ecosystems in multiple regions.

- **Europe** (60%) — Estimated from portfolio description and Stockholm base
- **Israel** (15%) — Explicitly mentioned as a portfolio geography
- **United States** (25%) — Explicitly mentioned as a portfolio geography

- Headquartered in Stockholm, Sweden
- Portfolio exposure across several European markets
- Investment presence in Israel and the United States
- Cross-border life science investing increases regulatory and valuation complexity
- Geographic diversification reduces dependence on any single market

## Strategy

Flerie’s strategy is active ownership: it takes board representation, works closely with management, and supports key decisions around development, financing, partnerships, and commercialization. The company focuses on life science opportunities where scientific impact, unmet medical need, and commercial potential overlap, while keeping a long-term investment horizon through its evergreen structure.

- **Active ownership and board involvement** (short-term) — Direct governance and operational input help portfolio companies progress faster and with clearer strategic direction.
- **Build value across the development cycle** (medium-term) — Supporting companies from early research through commercialization increases the chance of capturing long-term value creation.
- **Diversify the life science portfolio** (medium-term) — A broad mandate across modalities and stages helps balance scientific risk and commercial risk.

- Use active ownership to influence portfolio company development
- Focus on pharmaceutical development and adjacent life science services
- Support partnering, licensing, and commercialization milestones
- Maintain long-term capital through an evergreen structure
- Diversify across development stages and therapeutic areas

## Risks

Flerie’s main risks come from the valuation and financing characteristics of private life science investing, where outcomes depend on clinical progress, regulatory approvals, and market adoption. The company is also exposed to liquidity, credit, exchange-rate, and reporting risks because it holds a mix of listed and unlisted assets and uses fair-value estimates for a large part of the portfolio.

- **Valuation risk on private portfolio companies** [high] — Many holdings are unlisted and valued using judgment-based methods, so changes in assumptions can materially affect reported value.
- **Clinical and regulatory failure** [critical] — Product development companies depend on trial success, approvals, and commercialization pathways that may not materialize.
- **Liquidity and financing risk** [high] — Portfolio companies may require follow-on capital, while Flerie must manage its own funding and investment commitments.
- **Foreign exchange risk** [medium] — Investments span multiple currencies and jurisdictions, creating translation and transaction exposure.
- **Credit risk on receivables and loan exposures** [medium] — The company has financial assets such as loan receivables from portfolio companies that may require impairment assessment.

- Valuation risk from unlisted holdings and subjective fair-value inputs
- Clinical and regulatory risk in biotech and pharma development
- Liquidity and financing risk tied to portfolio funding needs
- FX risk from cross-border investments and capital flows
- Price risk is identified as the single greatest financial risk

## Accounting

Flerie’s reported results are heavily influenced by fair-value measurement of portfolio holdings, especially unlisted investments valued with Level 3 techniques and other judgment-based methods. The company also applies IFRS 16 for leases and expected credit loss accounting for receivables, while tax treatment depends on whether holdings are classified as business-purpose or taxable investments.

- **Fair value measurement of portfolio investments** — Net asset value and fair value gains/losses
- **Level 3 valuation methodology** — Reported investment carrying values
- **Expected credit losses on receivables** — Profit and carrying value of financial assets
- **Lease accounting under IFRS 16** — EBITDA, depreciation, and leverage presentation
- **Tax treatment of holdings** — Current tax and deferred tax

- Fair value estimates for unlisted holdings drive reported NAV and earnings
- Level 3 valuation inputs rely on management judgment and model assumptions
- Expected credit loss accounting affects loan receivables and other assets
- Lease accounting affects right-of-use assets and lease liabilities
- Tax classification of holdings affects current and deferred tax outcomes

---

*Last updated: 2026-08-11T04:04:52.679729+00:00*